431 related articles for article (PubMed ID: 29984391)
1. The role of CD133 in cancer: a concise review.
Glumac PM; LeBeau AM
Clin Transl Med; 2018 Jul; 7(1):18. PubMed ID: 29984391
[TBL] [Abstract][Full Text] [Related]
2. In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines.
Zito G; Richiusa P; Bommarito A; Carissimi E; Russo L; Coppola A; Zerilli M; Rodolico V; Criscimanna A; Amato M; Pizzolanti G; Galluzzo A; Giordano C
PLoS One; 2008; 3(10):e3544. PubMed ID: 18958156
[TBL] [Abstract][Full Text] [Related]
3. CD133 as a regulator of cancer metastasis through the cancer stem cells.
Liou GY
Int J Biochem Cell Biol; 2019 Jan; 106():1-7. PubMed ID: 30399449
[TBL] [Abstract][Full Text] [Related]
4. How powerful is CD133 as a cancer stem cell marker in brain tumors?
Cheng JX; Liu BL; Zhang X
Cancer Treat Rev; 2009 Aug; 35(5):403-8. PubMed ID: 19369008
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer.
Joseph C; Arshad M; Kurozomi S; Althobiti M; Miligy IM; Al-Izzi S; Toss MS; Goh FQ; Johnston SJ; Martin SG; Ellis IO; Mongan NP; Green AR; Rakha EA
Breast Cancer Res Treat; 2019 Apr; 174(2):387-399. PubMed ID: 30554343
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of stem cell marker CD133 expression in colorectal cancer.
Wang BB; Li ZJ; Zhang FF; Hou HT; Yu JK; Li F
Histol Histopathol; 2016 Mar; 31(3):299-306. PubMed ID: 26442717
[TBL] [Abstract][Full Text] [Related]
7. Impact of in vitro driven expression signatures of CD133 stem cell marker and tumor stroma on clinical outcomes in gastric cancers.
Kim TM; Ko YH; Ha SJ; Lee HH
BMC Cancer; 2019 Feb; 19(1):119. PubMed ID: 30717708
[TBL] [Abstract][Full Text] [Related]
8. New emerging roles of CD133 in cancer stem cell: Signaling pathway and miRNA regulation.
Aghajani M; Mansoori B; Mohammadi A; Asadzadeh Z; Baradaran B
J Cell Physiol; 2019 Dec; 234(12):21642-21661. PubMed ID: 31102292
[TBL] [Abstract][Full Text] [Related]
9. Photochemical internalization of CD133-targeting immunotoxins efficiently depletes sarcoma cells with stem-like properties and reduces tumorigenicity.
Stratford EW; Bostad M; Castro R; Skarpen E; Berg K; Høgset A; Myklebost O; Selbo PK
Biochim Biophys Acta; 2013 Aug; 1830(8):4235-43. PubMed ID: 23643966
[TBL] [Abstract][Full Text] [Related]
10. CD133 in Breast Cancer Cells: More than a Stem Cell Marker.
Brugnoli F; Grassilli S; Al-Qassab Y; Capitani S; Bertagnolo V
J Oncol; 2019; 2019():7512632. PubMed ID: 31636668
[TBL] [Abstract][Full Text] [Related]
11. Targeting Colorectal Cancer Stem-Like Cells with Anti-CD133 Antibody-Conjugated SN-38 Nanoparticles.
Ning ST; Lee SY; Wei MF; Peng CL; Lin SY; Tsai MH; Lee PC; Shih YH; Lin CY; Luo TY; Shieh MJ
ACS Appl Mater Interfaces; 2016 Jul; 8(28):17793-804. PubMed ID: 27348241
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of CD133 expression as a tumor-initiating cell marker in endometrial cancer.
Nakamura M; Kyo S; Zhang B; Zhang X; Mizumoto Y; Takakura M; Maida Y; Mori N; Hashimoto M; Ohno S; Inoue M
Hum Pathol; 2010 Nov; 41(11):1516-29. PubMed ID: 20800872
[TBL] [Abstract][Full Text] [Related]
13. CD133: a stem cell biomarker and beyond.
Li Z
Exp Hematol Oncol; 2013 Jul; 2(1):17. PubMed ID: 23815814
[TBL] [Abstract][Full Text] [Related]
14. The Expression Status and Prognostic Value of Cancer Stem Cell Biomarker CD133 in Cutaneous Squamous Cell Carcinoma.
Xu R; Cai MY; Luo RZ; Tian X; Han JD; Chen MK
JAMA Dermatol; 2016 Mar; 152(3):305-11. PubMed ID: 26560495
[TBL] [Abstract][Full Text] [Related]
15. Acquisition of tumorigenic potential and therapeutic resistance in CD133+ subpopulation of prostate cancer cells exhibiting stem-cell like characteristics.
Kanwal R; Shukla S; Walker E; Gupta S
Cancer Lett; 2018 Aug; 430():25-33. PubMed ID: 29775627
[TBL] [Abstract][Full Text] [Related]
16. New Insights into the CD133 (Prominin-1) Expression in Mouse and Human Colon Cancer Cells.
Sgambato A; Corbi M; Svelto M; Caredda E; Cittadini A
Adv Exp Med Biol; 2013; 777():145-66. PubMed ID: 23161081
[TBL] [Abstract][Full Text] [Related]
17. The most reliable surface marker for the identification of colorectal cancer stem-like cells: A systematic review and meta-analysis.
Abbasian M; Mousavi E; Arab-Bafrani Z; Sahebkar A
J Cell Physiol; 2019 Jun; 234(6):8192-8202. PubMed ID: 30317669
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological characteristics and prognostic value of cancer stem cell marker CD133 in breast cancer: a meta-analysis.
Li Z; Yin S; Zhang L; Liu W; Chen B; Xing H
Onco Targets Ther; 2017; 10():859-870. PubMed ID: 28243121
[TBL] [Abstract][Full Text] [Related]
19. In vivo investigation of CD133 as a putative marker of cancer stem cells in Hep-2 cell line.
Wei XD; Zhou L; Cheng L; Tian J; Jiang JJ; Maccallum J
Head Neck; 2009 Jan; 31(1):94-101. PubMed ID: 18853445
[TBL] [Abstract][Full Text] [Related]
20. Clinical and biological significance of stem-like CD133(+)CXCR4(+) cells in esophageal squamous cell carcinoma.
Lu C; Xu F; Gu J; Yuan Y; Zhao G; Yu X; Ge D
J Thorac Cardiovasc Surg; 2015 Aug; 150(2):386-95. PubMed ID: 26092504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
